Brought to you by 
Coronado forms Avenue Therapeutics subsidiary to license Revogenex's IV tramadol
11 Jul 2017
Executive Summary
Coronado Biosciences Inc. formed a new subsidiary, Avenue Therapeutics Inc., which licensed exclusive US development, marketing, and manufacturing rights to Revogenex Ireland Ltd.'s intravenous formulation of tramadol, including all related issued IP and pending patent applications for methods of administration.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Coronado forms Avenue Therapeutics subsidiary to license Revogenex's IV tramadol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice